HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elderberry Demand Loud But Matherson Organics Silent In NAD Review Of Immune Benefit Claim

Executive Summary

The National Advertising Division says it will refer Matherson Organics to regulators for possible enforcement after it failed to provide a substantive response to an inquiry on an Instagram claim that suggested Vitamin Bounty Elderberry Immune Support could help prevent or treat COVID-19.

You may also be interested in...

US HBW Business News: OTC Migraine Treatment Device Cleared, Nestle Closes Aimmune Deal, More

Cefaly touts first OTC dual-Purpose eTNS migraine device available in US; Nestle Health Science closes on its acquisition of Aimmune Therapeutics; Elderberry supplement marketer Matherson Organics complies with NAD recommendations rather than face FTC scrutiny; and nutrition product firm Vidafuel closes on $1.6m financing round.

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 

No Enforcement Immunity For Testimonials On Immunity Or Claims With 'Alert: No COVID-19 Cure'

Elderberry syrup marketer Provezza Health targeted review of claims consumers may link to COVID-19 prevention or treatment due to testimonials not dispelled by the firm. FDA and FTC warn CBD firm to discontinue claims noting immunity-boosting is the “best defense” against COVID-19.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts